Noorderhart

Pelt 16 trials 5 recruiting

16 Registered trials

5 Currently recruiting

Organisation

Noorderhart

Location

Pelt, Belgium

Identifier

ORG-100042021

Address

Boemerangstraat 2, 3900, Belgium

Departments

#2002: Neurology
9112 : Neurology
Neurology
Neurology department
Revalidatie & MS
Revalidatie en MS centrum

Clinical trials at this site (16)

Search interface

A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis Recruiting

2024-512707-40-00 RELAPSING MULTIPLE SCLEROSIS 4 2024-11-07
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 multiple sclerosis 5 2024-10-17
Non-inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple s… Recruiting

2024-519304-28-00 Multiple Sclerosis 5 2026-04-20
Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o… Recruiting

2023-509275-17-00 Relapsing multiple sclerosis 5 2025-10-06
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Progressive Multiple Sclerosis 4 2023-11-23
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19
A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant… Ended

2023-509078-45-00 Multiple sclerosis 4 2022-12-19
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended

2024-514495-41-00 Primary Progressive Multiple Sclerosis 5 2020-11-04
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended

2023-506543-41-00 Multiple sclerosis (MS) 5 2018-07-25